BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System - Gilde Healthcare

BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System

March 8, 2010

Waltham, MA—BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.
 
Under the agreement, Abbott will be responsible for the development of the test in accordance with certain plans and milestones, and BG Medicine and Abbott will collaborate in support of regulatory filings and studies to support the clinical utility of galectin-3 in the management of patients with acute decompensated heart failure.

“Heart failure is one of the most costly medical conditions. Despite important advances in diagnosis, there remain significant unmet needs in assessing patients with heart failure and selecting a course of action both in emergency room and non-acute care settings,”

said Pieter Muntendam, M.D., President and CEO of BG Medicine.

“This collaboration is an important step toward determining the exact role this test can play in assisting physicians in their efforts to improve outcomes and reduce cost of care.”

About BG Medicine (www.BG-Medicine.com)
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine’s proprietary technology platform enables rapid and cost effective discovery of new high?value diagnostics biomarkers over a broad range of therapeutic areas.

More news

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody visugromab, in combination with standard-of-care...
September 30, 2025